Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

FRIDAY, Aug. 8, 2025 (HealthDay News) — A new weight loss pill made by Eli Lilly helped people lose a significant amount of ...

Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...